Related references
Note: Only part of the references are listed.Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia
Evgenii Shumilov et al.
ACTA HAEMATOLOGICA (2021)
Advances and Perspectives in the Treatment of T-PLL
Till Braun et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)
Corey Cutler et al.
BLOOD (2020)
Chimeric Antigen Receptors for T-Cell Malignancies
Lauren D. Scherer et al.
FRONTIERS IN ONCOLOGY (2019)
Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies
Jinqi Huang et al.
LEUKEMIA (2019)
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation
Alexandra Gomez-Arteaga et al.
LEUKEMIA & LYMPHOMA (2019)
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study
Edmund K. Waller et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)
W. Wiktor-Jedrzejczak et al.
BONE MARROW TRANSPLANTATION (2019)
Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia
Fares Alsawah et al.
BLOOD ADVANCES (2019)
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
E. I. Andersson et al.
LEUKEMIA (2018)
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience
Bhagirathbhai R. Dholaria et al.
LEUKEMIA RESEARCH (2018)
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
A. Schrader et al.
NATURE COMMUNICATIONS (2018)
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
L. Sellner et al.
BONE MARROW TRANSPLANTATION (2017)
The immunological function of CD52 and its targeting in organ transplantation
Yang Zhao et al.
INFLAMMATION RESEARCH (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M. Maciocia et al.
NATURE MEDICINE (2017)
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
F. M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
Bernd Boidol et al.
BLOOD (2017)
Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC)
Thierry Guillaume et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
T-cell Prolymphocytic Leukemia Frequently Shows Cutaneous Involvement and Is Associated With Gains of MYC, Loss of ATM, and TCL1A Rearrangement
Andy C. Hsi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia
Mark J. Kiel et al.
BLOOD (2014)
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia
Georg Hopfinger et al.
CANCER (2013)
Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium
W. Wiktor-Jedrzejczak et al.
LEUKEMIA (2012)
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route
Claire E. Dearden et al.
BLOOD (2011)
Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia
Matt E. Kalaycio et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study
Biju Krishnan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
T-cell prolymphocytic leukemia: An aggressive T cell malignancy with frequent cutaneous tropism
Cynthia M. Magro et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia:: graft-versus-tumor effect and long-term remission
H de Lavallade et al.
BONE MARROW TRANSPLANTATION (2006)
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab
KA Thursky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories
M Herling et al.
BLOOD (2004)
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
CE Dearden et al.
BLOOD (2001)
Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation
L Garderet et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Share Paper
